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Acute Silica Toxicity: Attenuation by Amiodaroneinduced Pulmonary Phospholipidosis
James M. Antonini, Christy M. McCloud, and Mark J. Reasor
Department of Pharmacology and Toxicology, Robert C. Byrd Health Sciences Center,
West Virginia University, Morgantown, WV 26506 USA
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sis was that the increase in phospholipid levels within the lungs after the induction of

phospholipidosis will protect them from
damage caused by the exposure to cytotoxic
particles.
In this study, we induced pulmonary
phospholipidosis in rats using amiodarone
and determined that this increase in intracellular or extracellular phospholipid
reduced the acute toxic response in the
lungs when challenged intratracheally with
silica dust. In the measurement of the
inflammatory response of silica for our
study, a number of cellular and biochemical
endpoints in the bronchoalveolar lavage fluids were measured. Lavage of the bronchoalveolar region collects epithelial lining
fluid of the conducting airways and alveoli,
the sites of pulmonary contact for instilled
silica particles (4). Previous studies have
indicated analysis of the bronchoalveolar
lavage fluid is a sensitive means of characterizing acute inflammatory responses within
the lungs (26-28).
In this investigation, we also attempted
to determine the mechanism by which pulmonary phospholipidosis protects the lungs
from silica damage. To simulate our in vivo
experiments in this study, we used an in
vitro system where viability of amiodaroneinduced foamy AMs and normal, control
AMs was measured after incubation with
native silica or silica treated with Survanta, a
commercially available pulmonary surfactant. Survanta is a natural bovine lung
extract containing phospholipids, neutral
lipids, fatty acids, and surfactant-associated
proteins (29).

Materials and Methods
Amiodarone was a gift from Wyeth-Ayerst
Research (Princeton, New Jersey).
Crystalline Min-U-Sil silica (U. S. Silica
Corp., Berkley Springs, West Virginia) was
a gift from Val Vallyathan, National
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26506-9223 USA.
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Institute for Occupational Safety and
Health. Purity of the silica was determined
by automated X-ray diffractrometry and
was 99.5% alpha quartz. Size fraction of <5
pm in diameter was made by a centrifugal
airflow particle classifier. Of this fraction,
98% was <5 pm with a median area equivalent diameter of 3.5 pm as estimated by
automated scanning electron microscopic
image analysis. Survanta (Ross Laboratories,
Columbus, Ohio) samples were supplied by
the West Virginia University Department
of Pharmaceutical Services. It is the policy
of the pharmacy that, after use in human
patients, any remaining reconstituted samples of Survanta in opened vials is discarded. The Survanta samples used in this investigation represented unused drug that was
ready to be discarded. After use by the pharmacy, the unused surfactant samples were
frozen at -20'C and stored until ready for
experimentation. Enzyme reagents were
purchased from Sigma Chemical Company
(St. Louis, Missouri). Other chemicals used
in this study were from Fisher Chemical
Company (Pittsburgh, Pennsylvania).
The experimental design will be
described briefly, then detailed in subsequent sections. Male Fischer 344 rats were
treated by oral gavage with amiodarone or
water (pair-fed controls) for 14 days. We
intratracheally instilled silica suspended in
saline into one-half of each of the two
treatment groups. The remaining animals
received an intratracheal instillation of the
saline vehicle. Thus, for these experiments,
four study groups were used. The groups
and the designations used in this study are
as follows: 1) amiodarone-treated + silica:
A-SI; 2) water-treated + silica: W-SI; 3)
amiodarone-treated + saline: A-SA; and 4)
water-treated + saline: W-SA. Bronchoalveolar lavage was performed on the animals 1 and 14 days after the instillation
exposures. We assessed three basic indicators of pulmonary damage: a total and differential cell count to characterize the cellular aspects of inflammation; total protein
to quantify increased permeability of the
bronchoalveolar-capillary barrier; and the
activity of the lysosomal enzyme f3-glucuronidase to detect activated or lysed
phagocytes. To ensure that a phospholipidotic condition was induced by the amiodarone treatment, the total phospholipid
content of the cells and lavage fluid recovered from the lungs was also measured.
We obtained Male Fischer 344 rats
weighing 200-250 g from Hilltop Laboratories (Scottdale, Pennsylvania). Rats
were given a conventional laboratory diet
(Purina Chow Pellets) and tap water ad
libitum during a 5-day acclimation period.
We then treated the rats for 14 days with
150 mg amiodarone/kg of body weight,
per os, suspended in water (2 ml/kg body
Volume 102, Number 4, April 1994
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weight). Along with treated animals, an
equal number of control rats were dosed
with water in equivalent volumes for 14
days. Food was restricted from the control
rats to maintain comparable weights
between the groups because amiodarone
treatment causes a reduction in weight
gain. At the time the animals were ravaged,
the weights of all the animals in the study
were within 30 g of each other. To maintain the phospholipidotic condition, the
amiodarone (and water-control) treatments
continued after the intratracheal instillations of silica or saline vehicle until the
animals were ravaged.
We measured drug levels in the AMs
recovered from the animals treated for 14
days with amiodarone using HPLC as
described by Reasor et al. (9). For the
phospholipid assay, samples of cell-free
bronchoalveolar lavage fluid and alveolar
macrophages recovered from the animals
treated for 14 days with amiodarone were
extracted with chloroform/methanol (2/1,
v/v) as described by Folch et al. (30). Total
lipid phosphorous in the cells and the
bronchoalveolar lavage fluid was quantified
by the method of Ames and Dubin (31)
following ashing in 10% MgNO3 in 70%
ethanol to liberate inorganic phosphorous
from the lipid.
Before silica was instilled in the animals, it was cleaned by boiling in 1.0 M
HCl for 60 min. The silica was suspended
and sonicated for 15 min in 0.9% sterile
saline at a concentration such that each rat
received a constant dose volume of 0.5 ml
per rat. One-half of all rats used in this
study were dosed intratracheally with a single instillation of 2.5 mg or 10 mg/100 g
body weight of silica with a mean particle
size of <5 pm. In some preliminary studies,
these doses were shown to cause significant
acute toxicity. The remaining animals were
instilled with an equal volume of sterile
saline (vehicle control). We lightly anesthetized the rats by intraperitoneal injection of sodium methohexital, and using a
modified laryngoscope to illuminate the
larynx, intratracheally instilled each rat
with either the saline containing silica or
the saline vehicle.
On days 1 or 14 after instillation exposure, bronchoalveolar lavage was performed on the animals. The rats were
deeply anesthetized with an overdose of
sodium pentobarbital and exsanguinated
by severing the abdominal aorta. The lungs
of each rat were first ravaged with one separate aliquot of warm, calcium- and magnesium-free Hanks' Balanced Salt Solution
(HBSS), pH 7.4, which was left in the
lungs for 30 sec, aspirated, reinstalled for
an additional 30 sec and then withdrawn.
We used a volume of 2.0 ml/100 g of animal body weight for this savage to take

into account any variations in body
weights of the rats ravaged. This lavage
sample was centrifuged at 5OOg for 7 min,
and the resultant cell-free supernatant was
analyzed for various biochemical parameters. Additionally, the lungs were further
ravaged 10 times with 5-ml aliquots of
HBSS. These samples were also centrifuged for 7 min at 5OOg and the cell-free
lavage fluid discarded. The cell pellets from
all washes for each rat were combined,
washed, and resuspended in 2 ml of HBSS
buffer. We then counted and differentiated
the cells.
Total cell numbers were determined
using a hemacytometer. Using a Shandon
cytospin centrifuge, 1.5 x 10 cells were
spun for 4 min at 400 rpm and pelleted
onto a slide. Cells (200/rat) were differentiated on the cytocentrifuge-prepared slides
after staining with Wright Giemsa Sure
Stain (Fisher Scientific, Pittsburgh,
Pennsylvania). AMs, neutrophils, and lymphocytes were counted.
We determined the protein content of
cell-free bronchoalveolar lavage fluid samples by the method of Hartree (32) using
bovine serum albumin as the standard. We
assayed 9-glucuronidase activity in the cellfree bronchoalveolar lavage fluid by the
method of Lockard and Kennedy (33).
To determine the amount of phospholipid bound to silica in the lungs of control
and phospholipidotic rats, control and
amiodarone-treated rats were intratracheally instilled with a single 10 mg/100 g body
weight dose of silica as described above.
Bronchoalveolar lavage was performed on
the animals 1 day after the silica instillations. We used HBSS to lavage cells and
silica from the lungs of the animals. A total
of 80 ml of lavage fluid was recovered from
each animal and centrifuged at 1 Og for 3
min. The resulting pellet for each rat was
washed and resuspended in 0.5 ml HBSS.
The cell/silica suspension was placed on
top of a 1.0 ml dibutyl phthalate (d =
1.080 g/ml) cushion in a microfuge tube.
To separate the silica from the cells, we
spun the suspensions in a Beckman
Microfuge (Beckman Instruments, Palo
Alto, California) at a setting of 2 for 30
sec. The lavage cells remained on top of
the cushion, while the silica particles
formed a pellet on the bottom of the tube.
The cushion was drawn off by a Pasteur
pipette. The pellet was washed with saline
twice. A 2:1 volume/volume mixture of
chloroform and methanol was added to the
pellet and vortexed for 30 sec to extract the
phospholipid from the silica. We included
a blank which contained 20 mg silica not
instilled in the animals. The samples were
then spun in the microfuge for 5 min at a
setting of 10. For analysis of total phospholipid associated with the silica, 100-pl
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Figure 1. The accumulation of amiodarone and its
principal metabolite, desethylamiodarone, from
cells recovered from the lungs of rats. Animals
were treated for 14 days with an oral 150 mg/kg
daily dose of amiodarone. Values are means SE
(n= 4).
±

aliquots of the supernatant were added to
glass tubes in duplicate and dried
overnight. We quantified total lipid phosphorous by the method of Ames and
Dubin (31) as described above. An empty
microfuge tube was weighed before separating the silica on the phthalate cushion.
The phthalate was removed, the lipid was
extracted from the silica, and the silica was
dried. We then weighed the microfuge
tube with the silica pellet. The previous
weight of the empty microfuge tube was
subtracted from this value for the measurement of the amount of silica recovered
from the lungs of the animals. The phospholipid content of each sample was determined as pmol/mg silica.

In Vitro Cell Viability Study
The rats were treated daily for 14 days
with 150 mg amiodarone or water/kg of
body weight, per os (pair-fed controls), as
described above. AMs were recovered from
control and amiodarone-treated animals by
pulmonary lavage. The cells were resuspended in sterile culture medium (34) and
plated at a concentration of 1.0 x 106
cells/tissue culture well. We incubated
AMs from amiodarone-treated and control
animals with a 0.5 mg/ml concentration of
native silica or silica coated with the
Survanta. The surfactant-treated silica was
prepared by suspending the silica in
Survanta and incubating for 1 hr at 37°C.
The excess surfactant was removed from
the silica by centrifugation at 5OOg for 10
min according to the method of Wallace et
al. (35). The supernatant was removed, the
silica was washed with HBSS by centrifugation, and then resuspended in HBSS.
The amount of surfactant phospholipid
bound from this procedure was 0.012
0.002 pmol/mg silica (n 4).
We incubated cells with the native or
surfactant-coated silicas for 24, 48, and 72
hr at 37°C in a tissue incubator containing
=
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Figure 2. Total phospholipid content of the cells
recovered from the lungs of control and amiodarone-treated rats. Animals were treated for 14
days with an oral 150 mg/kg daily dose of amiodarone. The pair-fed control animals received
water. Values are means SE (n = 6). Mean value
of the phospholipid content of the amiodaronetreated animals was significantly greater than
control value (*p <0.05).

Figure 3. Total phospholipid content of the acellular bronchoalveolar lavage fluid (BALF) recovered
from the lungs of control and amiodarone-treated
rats. Animals were treated for 14 days with an oral
150 mg/kg daily dose of amiodarone. The pair-fed
control received water. Values are means SE (n
= 6). Mean value of the phospholipid content of the
amiodarone-treated animals was significantly
greater than control value (*p <0.05).

air and 5% carbon dioxide. After incubation, a 0.10% final concentration of
trypsin was added to each well, and the
plates were incubated for 5 min to remove

Multiple Range Test. The criterion for significance was p <0.05.

attached alveolar macrophages. Cell viability was measured on aliquots from each
well by trypan blue exclusion.

The levels of amiodarone and its principal
metabolite desethylamiodarone, were measured in the AMs recovered from the lungs
of animals treated for 14 days with 150
mg/kg/day of amiodarone (Fig. 1). The
14-day amiodarone treatment led to substantial accumulation of both amiodarone
and desethylamiodarone in AMs.
Treatment for 14 days with amiodarone
resulted in a fourfold increase in total
phospholipid in the cells (Fig. 2) and a
threefold increase in total phospholipid in
the extracellular lavage fluid (Fig. 3) recovered from the lungs when compared with
control animals that received water vehicle.
Treatment with silica alone (W-SI) at
the two doses used in this study caused a
significant increase in the total protein lev-

±

Statistical Analysis
Comparisons between the phospholipid
levels of the two treatment groups (Figs. 2,
3, 8) were made by the Student's t-test
analysis. For Figures 4-7 and Table 1,
comparisons were made among the different treatment groups used. The significance of the interaction among the treatment groups was analyzed by using twoway analysis of variance for each time
point at each dose. If significance was
observed, the significance between each of
the individual groups was analyzed by oneway analysis of variance using a Duncan's

±

Results

8

I.
I-

Post-instillation exposure
Post-instillation exposure
cell-free
bronchoalveolar
4.
Total
content
of
the
lavage fluid from the lungs of rats 1 and 14
Figure
protein
days after silica instillation (2.5 mg or 10 mg/100 g body weight). Half of the animals were pretreated for
14 days with an oral 150 mg/kg daily dose of amiodarone (AD). The control animals received water (W).
Silica or saline vehicle then were instilled intratracheally and AD administration continued. Values are
means SE (n = 4-8). At each time point for each silica dose used, groups with different symbols are significantly different (p<0.05).
±
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els of the cell-free bronchoalveolar lavage
fluid 1 and 14 days after exposure (Fig. 4).
This increase was reduced significantly at
both time points in the A-SI group of animals, which were pretreated with amiodarone and were then instilled with silica.
The protein levels of the group that
received both amniodarone and the high
dose of silica were, however, still elevated
significantly above the two control groups
(A-SA and W-SA). In contrast, when using
a 2.5 mg/ 100 g body weight dose of silica
and measuring the response 14 days after
exposure, the amiodarone-induced phospholipidosis completely prevented the
increase in protein in bronchoalveolar
lavage fluid caused by the silica.
The W-SI groups, which received silica
alone at both doses, had significantly elevated levels of fI-glucuronidase activity
within the cell-free bronchoalveolar lavage
fluid 1 and 14 days after exposure compared to the W-SA control group (Fig. 5).
The presence of the amniodarone-induced
phospholipidosis (A-SI group) attenuated
the silica-induced rise in fI-glucuronidase
activity from both doses. This reduction in
fI-glucuronidase activity was greatest at the
low silica dose group, although in neither
group was it complete. One day after the
instillation exposure, the A-SA group that
received both amniodarone and saline had a
significantly elevated level of fl-glucuronidase activity.
Mean total cell counts for all treatment
groups are presented in Figure 6. Compared to the W-SA group, significant
increases in total cell numbers were
observed for all time periods and dose regimens in the A-SI and W-SI treatment
groups. Increases were also seen in the ASA group of animals except at 14 days in
the low silica dose experiment. These findings indicate that both the silica and amiodarone treatment can individually increase
the number of cells in the lavage fluid of
rats. The cell number from combined
amniodarone and silica treatments (A-SI
group) was not different from the W-SI
group of animals.
Compared to the W-SA groups, neutrophils were significantly increased in the
AD-SI and W-SI groups of animals at both
time points and silica doses (Fig. 7). This
influx of neutrophils in the W-SI and A-SI
groups accounted for nearly all the increases in total cells. A significant increase was
also seen in the A-SA group 1 day after the
instillation exposure when compared to the
W-SA group for the small dose silica
group.
In analysis of other cell types, the W-SI
group also had significantly increased
numbers of lymphocytes in the lavage fluid
compared to the W-SA control (data not
shown). Amniodarone pretreatment did not
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Figure 8. Total phospholipid bound to silica particles recovered from the lungs of control and
amiodarone-treated rats. Animals were treated
for 14 days with an oral 150 mg/kg daily dose of
amniodarone (AD). The control animals received
water (W). Silica (10 mg/100 g body weight) then
was intratracheally instilled into each animal of
both groups. Values are means ± SE (n = 6). The
mean value of the phospholipid bound to silica
from the AD-silica group was significantly
greater than the value of the W-silica group

*P005).
protect against this response. No consistent
response pattern was observed when evalu-

ating the change in the number of AMs
(data not shown).

To measure the amount of phospholipid bound to the silica, control and amiodarone-treated animals were intratracheally

instilled with silica (10 mg/100 g body

weight). One day after the installation,
there was nearly a four-fold greater amount

of phospholipid associated with the silica
recovered from the animals that had developed amiodarone-induced pulmonary
phospholipidosis when compared with
control animals (Fig. 8).

In Vitro Cell Vilability Study
In an attempt to determine the mechanism
by which amiodarone-induced pulmonary
phospholipidosis protects the lungs from
the damage caused by silica, an in vitro

experiment was performed. AMs from
amiodarone-treated and control animals
were incubated for 24, 48, and 72 hr with
native silica or silica treated with Survanta
(Table 1). When incubating the AMs from
both treatment groups without silica for all
three time points, cell viability was greater
than 97%, and no significant differences
were observed between the cells from the
two treatment groups. When the cells were
exposed to native silica, a dramatic and
equal loss of viability was demonstrated in
the control and phospholipidotic AMs at
each of the three time points. In the cells
from the control group, the silica treated
with surfactant caused an exposure timedependent reduction in cell viability of
21%, 5i1%, and 68% at 24, 48, and 72 hr,
respectively. The silica treated with surfactant caused significantly less cytotoxicity to
the phospholipidotic AMs. A 7-10%
376
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Studies have demonstrated that exposure
of rats to silica increases the intra- and
extracellular compartments of pulmonary
surfactant phospholipid (36-38). These
investigations have indicated that this elevation in phospholipid is due to an
increase in the biosynthesis of the pulmonary surfactant. It therefore appears
that the increase in pulmonary phospholipid may be a mechanism by which the
lungs protect themselves when challenged
with silica. Clearly, an elevation in surfactant alone is inadequate to protect against
toxicity, as massive damage occurs while
phospholipid levels are elevated (4,38);
however, by increasing the phospholipids
within the cells and airways within the
lungs before the insult, it may be possible
to reduce the damage caused by the exposure to silica.
Vallyathan et al. (20) hypothesized that
the surface properties of silica may be
involved in its cytotoxicity. When silica is
inhaled, the free radicals present on the
surface of the silica can generate hydroxyl
radicals in the aqueous environment of the
lung, which may lead to the development
of cellular damage.
Several in vitro studies have been performed using phospholipids in an attempt
to coat the silica and reduce its cytotoxicity. Emerson and Davis (21) coated silica
with alveolar lining material and compared
the cytotoxicity produced with uncoated
silica. They demonstrated that the coated
silica was effectively phagocytized by the
AMs but was less cytotoxic than uncoated
silica. Consequently, they concluded that
inhaled silica particles that become coated
by surfactant lipids may reduce or delay
the AM toxicity. In another in vitro study

by Wallace et al. (22), the biological
responses of dipalmitoyl lecithin-modified
and native silica were compared. The findings of this investigation also indicated that
surface modification of the silica with
dipalmitoyl lecithin prevented the cytotoxicity of silica.
In another study by Schimmelpfeng et
al. (25), bovine and rat AMs were incubated in vitro with DQ12 quartz alone or in
the presence of dipalmitoyl lecithin. The
reaction of the cells of both species to the
untreated dust particles was similar qualitatively and quantitatively, with a loss of viability and release of lactate dehydrogenase
after incubation. In the presence of
dipalmitoyl lecithin, the toxicity of quartz
to the bovine AMs disappeared completely,
while the rat AMs were also protected, but
to a lesser degree. While such in vitro
experiments are consistent with the
hypothesis that surfactant may play a protective role against silica-induced pulmonary toxicity, the significance of this
process in vivo is unknown.
As we have demonstrated previously
(9,19,39), treatment of rats with amiodarone resulted in pulmonary phospholipidosis. This amiodarone pretreatment
caused a significant increase in the phospholipid levels within AMs and the cellfree bronchoalveolar lavage fluid. The present study was performed to investigate
whether preexisting increased levels of
phospholipids in the lungs induced by
amiodarone would protect them from
acute damage caused by the intratracheal
instillation of silica.
Within the bronchoalveolar lavage fluid,
a variety of cellular and biochemical parameters were measured to characterize the
acute inflammatory response caused by silica. Markers of pulmonary damage within
the acellular component of the lavage fluid
were assayed. Total protein and {9-glu-

Table 1. Percent viability of alveolar macrophages from amiodarone-treated and water-treated rats after
incubation with native silica and silica treated with surfactanta
Treatment groups
Amiodaroneb
H20b
Time
98.5 ± 1.0
98.7 ± 0.6
Control
24 hr
21.2 ± 2.8
28.2 ± 4.6
Silica
92.7 ± 2.6'
78.9 ± 2.9
Silica + Survanta
98.8 ± 0.8*
98.3 ± 1.1
Control
48 hr
23.4 ± 4.8
21.5 ± 3.7*
Silica
92.3 ± 1.4'
48.8 ± 4.4
Silica + Survanta
99.3 ± 0.5
97.5 ± 0.5
Control
72 hr
12.3 ± 2.8
7.9 ± 3.1*
Silica
90.3 ± 2.3
32.6 ± 3.9
Silica + Survanta

aSee text for methods.
b'Values are means ± SE (n = 4-5). At each time point for the cells from both treatment groups, the mean

values of the percent viability for the two silica groups are significantly different than the values of their
respective controls and the silica + Survanta groups (*p <0.05); the mean values of the percent viability of
the two silica + Survanta groups are significantly different from their respective controls (**p <0.05); and
the mean values of the percent viability of the two silica + Survanta groups are significantly different
from each other (tp <0.05).
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curonidase activity were analyzed. Total and
differential cell counts were also evaluated
on the cells recovered from the lungs. The
pneumotoxic response we demonstrated
with the silica instillation was consistent
with the study of Lindenschmidt et al. (4).
As in that study, pulmonary damage, as
measured biochemically, was still present 14
days after the silica instillations. When
using silica doses of 2.5 mg and 10 mg/100
g body weight, the alveolar phospholipidosis produced by amiodarone pretreatment
markedly attenuated the elevations of the
acellular lavage parameters indicative of
damage after silica instillation. This protection, which was virtually complete with the
low silica dose, was consistent 1 and 14
days after the silica exposure for total protein and 9-glucuronidase activity.
In the assessment of the cellular parameters of the lavage fluid, the silica instillation, at both doses, caused an increase in
the number of cells recovered from the
lungs at the two time points after the exposure. This elevation in cell number was due
largely to the influx of neutrophils into the
lungs. Although the increased phospholipids within the lungs reduced the biochemical indices of damage caused by silica, it had no effect in preventing this infiltration of neutrophils. In the study by
Lindenschmidt et al. (4), aluminum oxide
and titanium dioxide increased the number
of neutrophils in the lungs, but caused a
significantly lower degree of pneumotoxicity when compared with silica. As there
were no differences in the cellular response
of the two silica groups used in this study,
it appears the silica is reaching the same
areas within the airspaces of the lung. This
indicates that the protective effect of the
phospholipidosis is probably not due to a
difference in distribution of silica in the
lungs as a result of this condition.
Neutrophils appear within the pulmonary interstitium and the bronchoalveolar savage fluid within a day after the intratracheal instillation of silica. Chemotactic
substances released from AMs are a likely
explanation for the attraction of neutrophils to the lungs. The presence of neutrophils in the lungs is important because
of their potent ability to cause lung tissue
injury (5). Thus, it appears that the chemotactic signal which recruits the neutrophils into the lungs was unaffected by
phospholipidosis. Given that neutrophils
have been implicated in silica-induced lung
injury (40), it is conceivable that treatment
with amiodarone either directly or indirectly renders them less active.
Pulmonary surfactant, which is 9095% phospholipid, forms an insoluble film
on the surface of the alveoli of the lungs
(41). It is possible that an increase in the
amount of phospholipid coating the silica
Volume 102, Number 4, April 1994
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particles in the phospholipidotic lungs may
be involved in the protection against acute
silica damage. To further investigate this
idea, silica was intratracheally instilled into
the lungs of either control rats or amiodarone-treated rats that had developed pulmonary phospholipidosis. We found that
there was a fourfold greater amount of
phospholipid associated with the silica
removed from the lungs that had developed phospholipidosis when compared
with normal lungs. However, there was
still a measurable amount of phospholipid
bound to the silica recovered from the control lungs. Therefore, the presence of a
phospholipid coating alone on silica is
inadequate to protect against damage.
It may be that a silica particle that has
adsorbed surfactant is phagocytized by the
AMs without an immediate cytotoxic
effect. The coated particle then may be
subjected to phospholipase activity associated with the AMs. These enzymes have
been shown to be active on components of
surfactant. Hostetler et al. (42) indicated
that phospholipases can hydrolyze phospholipids, such as dipalmitoyl lecithin, present in surfactant. Thus, the removal of the
phospholipid coating of the silica by phospholipases may retoxify the silica, resulting
in damage to the AMs.
When AMs were incubated for 24, 48,
and 72 hr with native silica, the control
and phospholipidotic AMs were equally
sensitive to the cytotoxic action of the particles. Therefore, the presence of elevated
phospholipid within the phospholipidotic
cells provided no protection against the
cellular injury caused by silica. The phospholipidotic cells were, however, more
resistant to the cytotoxic action of the surfactant-coated silica than were the control
AMs. When exposed to surfactant-coated
silica, control cells lost viability in a timedependent manner, while the phospholipidotic cells were virtually unaffected over
the 3-day period. It may be that over the
exposure period, control alveolar macrophages digest a portion of the surfactant
from the surface of the silica, in effect
retoxifying the particles, resulting in loss of
cellular viability. Thus, the presence of a
surfactant coating on the silica particles
would delay, but not prevent, the cytotoxicity of silica. Within the phospholipidotic
cells, the inhibition of lysosomal phospholipases by amiodarone and desethylamiodarone effectively prevents digestion of
adsorbed surfactant from the silica, thus
preventing retoxification from occurring.
This scenario would be consistent with the
reduced cytotoxicity of surfactant-coated
silica toward the phospholipidotic cells and
offers an explanation for the protective
effect of the phospholipidosis against the
acute toxicity of Silica in vivo.

e

The significance of phospholipase inhibition is further illustrated by the fact that
the amount of surfactant bound to the silica in this experimental in vitro condition
was less than we measured on silica recovered from control animals where damage
was the greatest. This would suggest that
the increased quantity of phopholipid
bound to the silica in the phospholipidotic
rats may be of less significance than the
cellular phospholipase inhibition in protecting against acute silica toxicity in this
model.
In a recent editorial, Hook (43) speculated whether pulmonary surfactant plays a
role in the defense of the lungs. The results
of this study would support the idea that a
sustained elevation in acellular phospholipid in the airspaces and alveoli occurring
before silica exposure may delay the acute
toxicity of this dust.
The results of this study, however, are
only applicable for silica's acute toxic
response. The influence of the reduction in
the initial pneumotoxic response to silica
by the phospholipidosis on the eventual
development of fibrosis is unknown.
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